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1. Introduction  
Infective endocarditis (IE) is a threatening disease associated with a high risk of morbidity 
and mortality. The most etiologic agents are the bacteria followed by fungi. Fungal 
Endocarditis (FE) is an uncommon occurrence and the most severe form of IE, however, its 
rate has increased in recent decades.  The first report of FE after a mitral valve replacement 
was in 1964 (1) but there have been many cases reported in recent years indicating the 
importance of such infections (2-4).  Fungal endocarditis accounts for 1.3% to 6% of all IE 
cases (5-8).  Ranges between 1.7 to 3.8 per 100,000 person-years have been reported in 
different studies for mean annual incidence (5, 9). Increase in the number of cases of 
fungemia and FE has been seen during the last 2 decades (10, 11). Men are more at risk of 
infections than women (7, 12, 13), and younger persons (third to fourth decades of life) are 
in more risk factor. The incidence of FE varies based on the criteria and methods of 
diagnosis (5) and population under survey; in liver transplants (14) the incidence of FE after 
transplantation was 1.7%. The mortality rate was 72% (15) but is still high (about 50%) 
despite the treatments (7). In an international multicenter prospective cohort study that 
included 33 cases of Candida endocarditis treated between 2000 and 2005, the mortality rate 
was 30 % (16),  and in post-surgical invasive aspergillosis (17) and Aspergillus endocarditis 
the rate was too high (100%) even with combined medical and surgical therapy (2).  
Fungi are important causes of prosthetic valve endocarditis, responsible for 1%–10% of these 
infections (18). Also, there are reports that fungi are responsible for 9.6% of the early cases of 
prosthetic valve endocarditis (60 days after the insertion of prosthesis) and for 4.3% of late 
cases (>60 days after the insertion of prosthesis) (19, 20). The incidence of FE in culture- 
documented cases has been reported to range from 12% to 20% (21) or to 37.5% (22). 
Many fungal species cause FE, of which the most important are Candida albicans 60%-67% 
and filamentous Aspergillus spp. 20–30% (ratio rate 2/1) (7, 15, 23), In addition, non-albicans 
species of Candida, Torulopsis glabrata, Candida tropicalis, and other filamentus fungi like 
Aspergillus spp., Curvularia genuculata, Hormondendrum dermatitidis, Mucoracae, Scopulariopsis 
spp., Trichosporon spp. and Blastoschizomyces capitatus have been reported in the literature (10, 
15, 22, 24, 25). In some studies, the most common etiologic agent was different, as in 
Rubinstein E et al. Candida parapsilosis accounts for half of the culture-documented patients, 
whereas C. albicans and Candida stellatoidea account for 12%-15% only (21). Pneumocystis 
jiroveci caused fungal infection in 9% to 11% of all heart transplant recipients in the past, 
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The source of infection can be internal or external, the former usually with Candida spp. This 
organism is the normal flora of the patient’s body and causes contamination during the 
surgery, and is recognized as the catheter-related blood stream infection (27). However, 
conidia of the external agents could contaminate the tissues during the surgery or post 
operative contamination by environmental isolates present in high counts (17).   
Time of presenting of infection is different and maybe during the first 2 weeks in hospital 
period to months after heart surgery at home, and in some cases 12 years later (15). 
Diagnosis should be prompt because the time interval between the first symptom and 
hospital admission in some cases is long and may be one year (15). Early diagnosis could be 
helpful for the patients' survival. The onset of symptoms is usually about 2 weeks or less 
from the initiating bacteremia. 
Anatomical cardiac condition diseases (cardiac abnormality), intravenous drug abusers and 
open heart cardiac surgery are the top risk factors for the infections. There are many risk 
factors for progressive FE, including the use of multiple immunosuppressive drugs such as 
azathioprine, corticosteroids, cyclosporine A, and cyclophosphamide (12, 13, 15). 
Malignancy, exposure to multiple broad-spectrum antibiotics, prolonged use of intravenous 
catheters (28), use of high glucose concentrations intravenous catheters especially in 
premature neonates (29), rheumatic heart disease (22), previous bacterial endocarditis, prior 
surgery, prolonged intravenous hyper alimentation, pacemaker implantation, and 
reconstructive cardiovascular surgery are other risk factors (15,30-32). In some cases no 
predisposing factor has been identified (7, 33) 
The mechanism of endocarditis includes high turbulent blood flow due to cardiac 
abnormality or other risk factors (e.g., particulate material in the repeated injections of drugs 
in IV drug abusers) which disrupt the surface of endocardia and endothelium. The response 
of the body is repairing the damaged tissue with platelet-fibrin meshwork which is sticky 
and proper site for infection. After temporary bacteremia, it sticks to this meshwork and 
proliferation of organism causes the infection that invades the cardiac valves.  
Infective endocarditis is classified into definite, probable, and possible according to Pelletier 
and Petersdorf (34). Other classifications include definite, probable, possible and rejected by 
von Reyn (35) and definitive, possible and rejected by Duke criteria (36) (Table 1). Briefly, 
proven FE is defined as the isolation of fungi from the normally sterile sites, the blood or 
heart biopsy or vegetation, by culture and/or the evidence of fungal invasion of tissue by 
histopathological methods. Probable FE is defined as when the culture is negative for the 
infective agents, and clinical conditions of the respective patients are not recovered despite 
the administration of standard antibacterial therapy. Role of echocardiography, definition of 
rejected IE and major and minor clinical criteria were added to the previous definition in 
1994 (37).  According to Duke criteria, the diagnosis of definitive IE requires the presence of 
either two major criteria, one major and three minor criteria, or five minor criteria. 
2. Clinical manifestations 
The clinical manifestations of acute or sub-acute IE are related to the underlying 
pathophysiology of embolization, bacteremia/ candidemia, immunologic response, and 
valvulitis (30). Common clinical features are changing heart murmur, fever, and major 
peripheral emboli (common in fungal endocarditis) (10, 33). Some cases presented with the 
systemic symptoms associated with bacteremia include fever, tachycardia, septic shock; and 
the general symptoms and signs of cardiac involvement including chest pain, arrhythmias,  
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-Histologic evidence of vegetation on tissue from surgery or autopsy 
 
- Positive blood cultures with known underlying valvular heart disease 
and evidence of emboli to viscera or skin  
- OR fever >38ºC with negative blood cultures in individuals, embolic 
phenomena and new regurgitant valvular heart murmurs  
 
- Positive blood cultures with known underlying heart disease 
- Embolic phenomena; or negative blood cultures with fever, known 
underlying valvular heart disease, and embolic episodes. 
  
- Many patients with clinical features of infective endocarditis did not 
meet the above criteria due to lack of sensitivity. 


































- Histologic evidence from surgery or autopsy 
- Positive bacteriology evidence of valvular vegetation or peripheral 
embolus (staining or culture). 
 
-Persistently positive blood cultures plus one of the following: New 
regurgitant murmur and predisposing heart disease, vascular 
phenomena, negative or intermittently positive blood cultures,  plus three 
of the following: new regurgitant murmur, fever, vascular phenomena - 
petechiae, Roth spots, Osler's nodes, Janeway lesions, splinter 
hemorrhages, aseptic meningitis,  conjunctival hemorrhages, 
glomerulonephritis, or central nervous system, pulmonary, coronary or 
peripheral emboli.  
 
-Persistently positive blood cultures plus one of the following: 
predisposing heart disease - definite valvular or congenital heart disease, 
or a cardiac prosthesis (excluding permanent pacemakers) , vascular 
phenomena  
-Negative or intermittently positive blood cultures with all three of the 
following: fever, predisposing heart disease, vascular phenomena.   
-Only for viridans streptococcal endocarditis: fever with at least two 
positive blood cultures without an extra cardiac source 
 
-Endocarditis unlikely, alternative diagnosis generally apparent or 
endocarditis likely, empiric antibiotic therapy warranted  
- Culture negative diagnosed clinically as endocarditis, but excluded by 
postmortem 
 
- Lacked prospective validation, but improved the specificity of the 
classification system, a large proportion of cases being classified as 
probable or possible (most patients do not require valve surgery). 
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Possible IE  
 
Rejected IE  
 
 
- Persistently positive blood cultures for organisms, new or partial 
dehiscence of a prosthetic valve or an abscess in the tissues surrounding a 
heart valve, presented of vegetation or other typical findings of 
endocarditis in echocardiography; new regurgitate murmur, serological 
or culture evidence of infection with Coxiella burnetii.  
 
- Positive blood cultures that do not meet the strict definitions of a major 
criterion, fever, predisposing valvular conditiona 
- OR intravenous drug abuse, elevated erythrocyte sedimentation rate and 
C-reactive protein hematuria and splenomegaly. 
 
 - Pathological criterion: vegetation or intracardiac abscess, confirmed by 
histology showing active   endocarditis, positive Gram stain results or 
cultures of specimens obtained from surgery or autopsy 
- Clinical criteria: 2 major criteria OR 1 major and 3 minor criteria OR 5 
minor criteria  
 
- 1 major criterion and 1 minor criterion OR 3 minor criteria 
 
- Firm alternate diagnosis for manifestations of endocarditis  
- Resolution of manifestations of endocarditis, or no pathologic evidence 
of infective endocarditis at surgery or autopsy after antibiotic therapy for 
four days or less  
- Does not meet criteria for possible infective endocarditis, as above 
a Prosthetic heart valve or a valve lesion that leads to significant regurgitation or turbulence of blood 
flow; Vascular phenomenon like emboli to the brain or organs, hemorrhages in the mucous membranes 
around the eyes; Immunologic phenomenon include lesions such as Roth's spots or "Osler's nodes and 
glomerulonephritis. 
Table 1. Definition of three criteria for the diagnosis of infective endocarditis 
edema, dyspnea, murmur on examination, cardiac failure, and persistent sepsis would also 
present. Other symptoms include abdominal pain, malaise, weight loss, night sweats, 
arthritis, finger clubbing, cough, hemoptysis, sudden death, coagulopathy, jaundice, nausea, 
hypotension, and renal failure.  Candida spp. is the most etiologic agent of FE; therefore, 
patients can present endophthalmitis, meningitis, osteomyelitis and other complications of 
candidemia. The more specific cutaneous or mucocutaneous lesions of IE include  Osler’s 
nodes, Roth spots (rare), and Janeway lesions  are more specific signs but less common and 
not diagnostic . Petechiae and splinter hemorrhages (nonblanching, linear reddish-brown 
lesions found under the nail bed) are not specific but are common skin manifestations. They 
may be present on the extremities of skin, or on mucous membranes. Other organs may be 
involved due to embolic events such as splenic or renal infarcts, or immune reactions like 
arthritis and glomerulonephritis, or spread by the blood passing to other organs like soft 
tissues, vertebral osteomyelitis, and the brain causing meningitis and/or encephalitis.  
3. Diagnosis of fungal endocarditis 
The diagnosis of IE is based upon high index of suspicion, careful history and physical 
examination, echocardiographic or histopathological findings, laboratory results, and chest 
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radiography. Gold standard tests for the detection of documented infections are the 
isolation of fungi from the blood, heart biopsy or vegetation by culture and the presence of 
tissue invasion by histopathology. Isolation of fungi from blood samples is difficult due to 
non-growth of fungal etiologic agents in blood culture. The rate of culture positive of 
Candida spp. in the blood is about 50% of the documented cases and positive blood culture 
for Aspergillus is rare (38-40). Fungi are cleared rapidly, due to large size, in the blood by the 
host’s reticuloendothelial system; therefore, the blood culture results are negative in many 
suspicious patients. The use of lysis-centrifugation system (41), or Bactec blood culture (42), 
may help the isolation of fungal agents but none is recommend as a standard method. Heart 
tissue is the best sample for the isolation of fungal agents. As resistance to the antifungal 
agents has been reported in many studies (43-45), in case of positive culture, sensitivity test 
of the isolated fungi to antifungal agents can contribute to the best management of 
infections.  
Another definitive microbiologic diagnosis depends upon the evidence of fungal tissue 
invasion with histopathologic investigation. The samples (tissue valve or emboli) are stained 
with specific stains like Gomori methenamine silver or Periodic acid-Schiff. With 
histopathology examination, morphological differentiation between Aspergillus spp. and 
other fungi is not completely available. 
Given the frequent negative blood cultures, and difficulty in obtaining the material from the 
surgical sites in the operating rooms, echocardiography, either transthoracic 
echocardiography (TTE) or transesophageal echocardiography (TEE), are used as the 
diagnosis tools with the sensitivity of about 77% (15) for the evaluation of FE and the 
presence of vegetation, based on the major diagnostic Duke criterion. Echocardiography can 
also detect intra cardiac abscess, new or progressive valvular regurgitation, the size and 
location of vegetation.  The size of vegetation may be small, medium, or large and anatomic 
site of the vegetation may be aortic valve, on tricuspid, mitral or endocardium, or on the 
previous aortic valvular surgery.  
Transesophageal echocardiography should be considered as the standard diagnostic 
procedure for IE (46). This method is able to evaluate the prosthetic valves, intracardiac 
complications, inadequate TTE, fungemia or bacteremia, and has superior sensitivity (47), 
compared to TTE, but significantly more invasive and expensive than it. Transthoracic 
echocardiography is the first line procedure for the detection of FE especially in native valve 
and prosthetic valve vegetations, and local extension of infection. The sensitivity of TTE in 
infants and younger children is about 80 percent (48, 49), therefore, the negative result of it 
cannot definitively rule out FE and examination should be repeated in respective patients. If 
there is a high clinical suspicion for FE and the TTE is negative, we should turn to TEE. 
Once treatment is completed, repeated evaluation may be necessary to establish a new 
baseline of valvular and myocardial functions for the patient. Unfortunately, both TTE and 
TEE may yield false negative results if the vegetations are small, or large size of the 
vegetation suspected as a mural thrombus, vegetation is attached to the mural endocardium 
and if embolization of the vegetation has occurred. 
Chest radiography and echocardiography are not useful in the diagnosis of IE; x-ray may 
present the septic pulmonary emboli (Minor Duke’s Criteria) and echocardiography may 
show evidence of some complications.  
Over the last several decades, non-culture laboratory methods have been directed at the 
development for the diagnosis of systemic fungal infections such as FE. Serological 
diagnostic methods can serve as the non-invasive methods for detecting the circulating 
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fungal antigens, fungal metabolites, or antibody in the blood (50, 51). The major limitation of 
these methods is unavailability to detect some fungi like Mucor spp. 
Galactomannan (GM) is a more promising circulating fungal antigen used to detect fungal 
infections especially invasive aspergillosis, but it is an exoantigen released from the tip of 
mycelium of many fungi spp. during growth (52), therefore, cross-reactivity has been 
described with other fungi (53-55). False negative reactivity without any known reason (56) 
and false positive reactivity with use of some drugs and foods have been reported (57-61). 
Sensitivity range of GM test, for the diagnosis of documented invasive aspergillosis cases 
was reported to be between 50.0% (62) and 90.6% (63).  There are limited studies using this 
method for the diagnosis of FE. In one study, GM test to establish the diagnosis of invasive 
aspergillosis was only positive (≥1 ng/mL) in 2/7 patients with endocarditis and 
mediastinitis(17) and four out of nine cases in another study (33).  To diagnose systemic 
candidiasis, enolase (64), phospholipase and proteinase enzymes (65), Candida mannan 
antigen (66, 67), and β-D-glucan (68-71) have been detected in some studies. However, there 
are a few reports on the use of such antigens in patients with FE. 
Antibody assays can be helpful for some species of fungi which are not the normal flora but 
there are problems with both specificity and sensitivity when Candida spp. is responsible for 
infections, since it is a part of the body normal flora. Immunosuppressed hosts may be 
unable to produce strong antibodies; therefore, the sensitivity of the assay in this high-risk 
population is decreased.  
The current focus of non-culture methods is on the development of a polymerase chain 
reaction (PCR) assay for the detection of fungal infections (72, 73). Panfungal PCR with 
universal primers (74), nested PCR (75, 76) and real-time PCR (77, 78) can serve as sensitive 
and quantitative methods to detect fungal DNA in the human blood specimens (74, 79). The 
sensitivity and specificity of nested PCR for invasive aspergillosis in the blood are 92.8% and 
94%, respectively (55). Although these methods have not been standardized and are not 
widely used, limited studies indicate a good sensitivity for FE diagnosis and close to blood 
cultures (33, 80). Using the molecular methods with reduced PCR steps like real time- PCR, 
the result can be released within 6 hours (81). Due to the inhibitory factors in human blood 
samples, PCR may yield false negative (82) and for the abundant conidia of fungi in the 
environment, false positive may also be seen, which is rare and limited.  The significance of 
PCR tests is their ability to detect fungal infections in early stages (83).  
Other nonspecific laboratory outcomes include: a normochromic normocytic anemia, 
elevated erythrocyte sedimentation rate and C-reactive protein indicative of inflammation, 
elevated rheumatoid factor titers (minor Duke criteria), hematuria and proteinuria (minor 
Duke criteria). 
Totally, in patients suspicious to FE, microscopy examination and culture of tissue materials 
obtained from heart surgery, with antifungal susceptibility test on the isolated fungi are the 
best methods for the diagnosis and management of FE. In patients with suspected FE in 
early stage of infection, use of nonaggressive method (i.e., serologic or molecular) is 
recommended. Combination of serological and microbiological tests is more useful if we are 
to avoid over-treatment.  
4. Treatment  
The high mortality rate, difficulty in sterilizing large fungal vegetation or abscesses, and 
the risk of embolization associated with medical therapy alone (84) are the reasons for the 
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recommendation of combined surgical and medical treatment in patients with FE for 
better prognosis (7, 8, 85). It is also the suggestion of the 2009 Infectious Diseases Society 
of America guidelines for the treatment of native and prosthetic valve Candida 
endocarditis (86). However, there are some reports of Candida endocarditis in which 
medical treatment alone proved successful (85, 87-89) with either caspofungin alone or in 
combination with flucytosine or fluconazole (87-90). The higher dose of antifungal agents 
than normal dose is recommended for treatment (86). In critically ill patients for whom 
surgical resection cannot be done, antifungal therapy is recommended for months and 
even life-long. In combination therapy a minimum of 6 weeks medication after surgery is 
advocated (91), but the treatment should be continued till signs and symptoms of the 
infection disappear and radiographic abnormalities are stabilized, and life-long 
prophylactic therapy is recommended.  Relapses are common either with medical or 
combined therapy (37, 92, 93) and may appear early or late; mean 25 months (92). Due to 
high relapse rates, patients should receive life-long therapy (92, 93) and careful follow-up 
is also essential for successful therapy.  
Treatment of FE in immunocompromised patients needs to take into account the 
underlying disease of patients and the intervention of antifungal agents with the patient's 
condition. For example, use of amphotericin B deoxycholate, in patients with renal 
insufficiency or those who are on multiple nephrotoxic drugs is not suggested and for 
fewer adverse effects, lipid formulations of amphotericin B are recommended (94). Many 
studies have  reported the resistance of some fungi to this antifungal agent (44, 45, 95), 
therefore,  to limit the use of amphotericin B, current treatment options including azole 
due to its broad antifungal activity, and echinocandins as a new class of antifungal drugs, 
are recommended (96).  
In transplant recipients and HIV patients, use of triazoles which have interaction with 
human P450 cytochromes (97),  can block the metabolism of certain anti-HIV drugs and also 
some drugs such as cyclosporine, statins, and benzodiazepines (98). Therefore, close 
monitoring of drug levels needs to be calibrated with the dose of immunosuppressive drugs 
(99, 100). Physicians should prescribe triazole agents in consultation with a pharmacist 
because inhibitory activities among triazoles are different and fluconazole is of less active 
inhibition of P450 than other azole agents such as itraconazole, voriconazole, and 
posaconazole. In patients receiving these antifungals, monitoring of drug levels in respective 
sera is suggested (96).  
Echinocandins; caspofungin, micafungin, and anidulafungin; are new antifungal agents 
which damage the fungal cell walls by inhibiting the b-(1, 3)-glucan synthesis. Drug–drug 
interactions between echinocandins such as caspofungin are observed with tacrolimus and 
cyclosporine, certain anti-HIV drugs and rifampin (96). Use of caspofungin in patients with 
impaired liver function and those receiving cyclosporine should be carefully considered, 
because of the common side effects of this agent including increased liver enzymes, 
pruritus, facial swelling, headache and nausea. They have fungicidal activity against Candida 
biofilm (101) and most isolates of Candida species including C. glabrata in vitro and in vivo 
with benign toxicity profile (102).  
If the patients are not responsive to their initial mono-antifungal therapy regimen, the use 
of the combination antifungal regimen is recommended that include an echinocandins 
with voriconazole or liposomal amphotericin B. Combination therapy by amphotericin 
B and a triazole is not suggested in the literature (103). The function of combination 
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antifungal therapy is controversial due to probable increase in side effects and toxicity 
level (104, 105). 
5. Prevention 
Fungal endocarditis may be caused by endogenous or exogenous fungi. The prevention of 
FE could be through adopting two strategies; one is general and useful for all infections like 
hand-washing, personal hygiene, and indwelling central venous catheters care, and the 
other is especially for fungal infections. Practical ways to achieve this goal is use of non-
drug or drug prevention (prophylaxis). Avoiding opportunistic endogenous agents like 
Candida spp. which colonize in the human body sites is difficult. The best strategy for the 
management of Candida endocarditis is the evaluation of colonization pre-surgery to 
determine the susceptibility pattern of the isolated organisms, which may cause  infection 
after surgery and enhance the success of management of systemic or endocarditis 
candidiasis. Care of central venous catheters is important for reducing candidemia and 
Candida endocarditis; and the removal of all existing central venous catheters for the 
reduction of morbidity and mortality (106-108) is helpful. However, in patients with obligate 
central venous access, new sites should be obtained (109, 110).  
Fungal spores are abundant in the environment, and unfiltered air, dust, and contaminated 
materials are full of fungal conidia (111, 112). In many cases, fungal infections may occur 
during the surgery, via contaminated air, surgical site or equipment with conidia. To 
prevent the contamination, use of high-efficiency particulate air filters for air sterility (113), 
and sterile equipment in the operation room are recommended.   
Antifungal prophylaxis could be used to avoid the development of fungal infections in high 
risk patients (114), based on the susceptibility patterns of the etiologic agents in each region. 
Empiric therapy (antifungal treatment of febrile patients at risk for infections) was first 
introduced to prevent invasive fungal infections in the 1980s in patients with undiagnosed 
fevers, particularly invasive candidiasis (115). To prevent the relapse in patients with history 
of fungal infections who have received complete antifungal therapy, clinicians can turn to 
secondary prophylaxis. 
6. Conclusion 
Fungal endocarditis is one of the most serious manifestations of invasive fungal infections. 
The first line of prevention is decreasing fungal conidia transition during surgery in 
operating rooms by using high-efficiency particulate air filters and sterile equipment. Early 
diagnosis and immediate appropriate antifungal therapy are critical for the survival of the 
respective patients. For high quality care of the patients, echocardiography with non-
cultural methods such as GM assay and PCR which can detect infection in early stages 
should be performed. In patients with suspected FE and positive test results, it is 
recommended that they receive antifungal agents pre-operation and also the clinical 
management be continued once the documented diagnosis is made based on the sample 
obtained in the operation room. As high relapses are common, treatment should be followed 
by careful review of the clinical, mycological (serum GM level and DNA load) and 
echocardiography sign and symptoms of the infections.  
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